Targeting prodromal Alzheimer’s disease: too late for prevention?

Prodromal Alzheimer’s disease is a novel area of research, with clinical research definitions still under development. The LipiDiDiet trial,\(^1\) published in The Lancet Neurology, was one of the first completed trials based on the International Working Group (IWG-1) criteria for prodromal Alzheimer’s disease.\(^2\) The study was a non-pharmacological intervention (medical food Souvenaid) in prodromal Alzheimer’s disease.

Fortasyn Connect, the active component of Souvenaid, was developed based on the premise that a specific combination of nutrients enhances synaptic functions.\(^3\) Fortasyn Connect consists predominantly of omega 3 (1500 mg per day of docosahexaenoic acid and eicosapentaenoic acid), phospholipids, choline, high doses of vitamin B (B12, B6, and folic acid), vitamin E, vitamin C, selenium, and uridine monophosphate. Souvenaid is a marketed product of Nutricia and is taken as a once-a-day drink with breakfast.

Three Fortasyn Connect trials have been done in patients with mild-to-moderate Alzheimer’s disease. In Souvenir I,\(^4\) 225 drug-naive patients with mild Alzheimer’s disease participated in a randomised, double-blind, controlled trial of Fortasyn Connect versus placebo for 12 weeks. There was a significant improvement in one of the coprimary outcomes (delayed verbal recall task), but not in the 13-item modified Alzheimer’s Disease Assessment Scale cognitive subscale or other cognitive outcomes.\(^4\) The Souvenir II study\(^5\) was a 24-week, randomised, double-blind, controlled trial in 259 drug-naive patients with mild Alzheimer’s disease. The primary outcome, neuropsychological test battery (NTB) memory domain Z score, was significantly improved in the active compared with the control group, but the composite NTB total composite Z score was not significantly different.\(^5\) In the S-connect study,\(^6\) add-on intake of Fortasyn Connect for 24 weeks did not slow cognitive decline in 527 people with mild-to-moderate Alzheimer’s disease.

In LipiDiDiet,\(^1\) 311 people with prodromal Alzheimer’s disease were randomly assigned to Fortasyn Connect or a control isocaloric drink for 24 months. The primary outcome was the change in the NTB composite score. Secondary outcomes included NTB Z scores, progression to Alzheimer’s disease dementia, clinical dementia rating sum of boxes (CDR-SB), and atrophy rates on MRI. No statistically significant differences were observed between the active and control groups for the primary outcome or four of the secondary outcomes. Two of the secondary outcomes suggested that Fortasyn Connect had a beneficial response: there was less worsening in CDR-SB in the active group (mean change of 0·56 [SD 1·32]) than in the control group (1·12 [1·72]) with an effect size of 0·33 (p=0·005), and supplementation with Fortasyn Connect slowed hippocampal atrophy rate with an effect size of 0·22 (p=0·005). However, 59 (37%) participants in the control group and 62 (41%) in the active group were diagnosed with dementia during the trial.

Several important lessons can be learned from the LipiDiDiet trial. First, LipiDiDiet, together with past trials, does not provide sufficient evidence for the use of Fortasyn Connect in mild or prodromal Alzheimer’s disease. The suggestion of benefit in two of the secondary outcomes is encouraging, but needs to be confirmed in further research.

Second, most of the participants who were screened were included in the trial, which was attributed to participants primarily coming from memory clinic populations with recent detailed assessments. Although this approach enhanced the selection of this group of individuals, it limits the external validity of this study outside of specialised memory clinics.

Third, baseline memory scores were very similar to mild Alzheimer’s disease, with a higher-than-expected conversion rate to Alzheimer’s disease during the trial. Despite this extent of impairment, changes in the primary outcome were not significant. This result indicates the limitations and challenges of constructing composite outcomes in the absence of validated data relevant to the population studied.

Fourth, the intervention appears to be targeting the disease at a late stage. A preplanned analysis in LipiDiDiet suggested that better baseline cognitive function (Mini-Mental State Examination score ≥26) was associated with a better drug placebo response in CDR-SB, hippocampal volume, and the primary endpoint in the per-protocol analysis.
Prodromal Alzheimer’s disease defined by the IWG-1 criteria requires evidence of neurodegeneration, such as medial temporal lobe atrophy, for inclusion into the study. As neurodegeneration progresses, the ability of preventive therapies to reverse progression to Alzheimer’s disease is attenuated. Identification of people at risk of Alzheimer’s disease, but who have no evidence of significant neurodegeneration, is crucial to the success of preventive strategies. Sensitive and less invasive biomarkers are needed to correctly identify Alzheimer’s disease at its earliest stages for long-term prevention interventions.

Hussein N Yassine
Keck School of Medicine of USC, Los Angeles, CA 90033, USA
hyassine@usc.edu

HNY reports grants from the National Institute of Aging (R01AG055770, R01AG054434), and the Alzheimer’s Association (NIRG-15-361854).

Eculizumab: a treatment option for myasthenia gravis?

Eculizumab is an expensive, humanised monoclonal antibody against the terminal complement protein C5. The drug was patented in 2007, and has since been used and approved for two rare diseases, paroxysmal nocturnal haemoglobinuria and atypical haemolytic uremic syndrome. Additionally, eculizumab has been used off-label, which constitutes up to a half of its use in some countries, for at least 25 different conditions. Refractory and generalised myasthenia gravis with anti-acetylcholine receptor antibodies is a rare disease that involves the complement system and for which eculizumab has a potential effect.

In The Lancet Neurology, James F Howard Jr and colleagues present results from the high-quality REGAIN study of 125 patients with anti-acetylcholine receptor antibody-positive refractory myasthenia gravis, of whom 62 received the active drug. Although the primary efficacy endpoint, improvement in activities of daily living (MG-ADL) compared with the placebo group, was not met (rank-based treatment difference -11.7, 95% CI -24.3 to 0.96; p=0.0698), several secondary endpoints showed a potential benefit for eculizumab. The improvement appeared during the first 4 weeks of treatment and lasted for the 6 months of the study. The drug appeared safe, in line with expectations from previous use. Severe infections represent a rare threat, but were not seen in this study.

The degree of improvement induced by eculizumab represents a major question. Results from REGAIN showed that 60% of the patients receiving eculizumab achieved a clinically meaningful response regarding daily activities (≥3 point improvement in MG-ADL), compared with 40% of the patients receiving placebo. There was large variation in response, with a fifth of the patients experiencing an excellent effect (≥8 point improvement in MG-ADL) of eculizumab, but also with one patient developing a myasthenic crisis.

The patients included in REGAIN belonged to two myasthenia gravis subgroups: early onset and late onset myasthenia gravis with generalised disease and anti-acetylcholine receptor antibodies. All patients had moderate or severe symptoms, and they had already used at least two immunosuppressive treatments. However, the included patients should not be regarded as refractory to treatment. The well-established myasthenia gravis drugs mycophenolate mofetil, methotrexate, cyclosporin, tacrolimus, and cyclophosphamide had been used by only a minority before enrolment. Rituximab, a chimeric anti-CD20 monoclonal antibody that specifically...